Coronary Artery Disease (CAD)POSSEMNCT07864051
Predicting Plaque Growth Using Blood Flow Stress Markers: A Proof-of-Concept Study
A study testing PCCTA scan and Endothelial cell isolation from peripheral blood sample in people with Coronary Artery Disease (CAD), run by Queen Mary University of London at 1 site in United Kingdom.
Trial summary
Coronary artery disease occurs when fatty deposits (plaques) build up inside the arteries that supply blood to the heart. Some plaques remain stable, while others continue to grow or become more likely to rupture, which can lead to a heart attack. Read more about this study
- Who is it for?
- Ages 40 years and older
- Conditions the study is for
- Coronary Artery Disease (CAD)
- What is being tested?
- PCCTA scan and Endothelial cell isolation from peripheral blood sample
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 270 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 17 Sep 2026to 17 Sep 2031
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age ≥40
- Stable angina, defined as typical symptoms with evidence of reversible ischemia in non-invasive test and/or documented obstructive coronary artery disease on coronary angiography (>70% stenosis of at least one major epicardial coronary artery or positive fractional flow reserve study)
- Patient that is willing and can provide written informed consent.
Who cannot join
- Acute coronary syndrome within <3 months
- Estimated glomerular filtration rate (eGFR) <60ml/min/1.73m²
- Previous coronary artery bypass surgery
- Decompensated heart failure, or left ventricular ejection fraction ≤30%
- Patient allergic to contrast or cannot receive treatment with aspirin, heparin, or thienopyridines
- Anticipated life expectancy <2 years
Show all 11Show fewer
- Flow limiting coronary artery disease in the proximal segments of all the 3 epicardial coronaries
- History of heart transplantation
- Patient that requires surgical revascularization
- Extensive coronary artery disease (i.e., multiple chronic total occlusions) or tortuous coronary anatomy that does not allow assessment of the coronary arteries with intravascular imaging
- Pregnant women will be excluded. All women of childbearing potential will undergo a pregnancy risk assessment and a urine pregnancy test prior to the 12-month PCCTA scan, in line with standard clinical practice for all PCCTA scans.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United Kingdom1 site, 1 recruiting
- Recruiting
Queen Marys University London
London, EC1M 6EU
Paul C Evans, +447825611695, paul.evans@qmul.ac.uk
Paul C Evans, PhD
About this study
Official title: Plaque Prediction Obtained With Shear Stress Endothelial Metrics: A Proof of Principle Study
Coronary artery disease occurs when fatty deposits (plaques) build up inside the arteries that supply blood to the heart. Some plaques remain stable, while others continue to grow or become more likely to rupture, which can lead to a heart attack. Identifying plaques that are at higher risk of progression could help doctors provide earlier and more personalized treatment.
The purpose of this study is to determine whether combining information about blood flow within the coronary arteries with information about a person's biological response to blood flow can improve prediction of plaque growth. Participants undergoing treatment for coronary artery disease will have a specialized heart scan to assess blood flow patterns around plaques in their coronary arteries. Researchers will also collect blood samples to study cells that line blood vessels and investigate how these cells respond to blood flow forces.
The study will follow participants over time to determine whether plaques are more likely to progress in individuals who show a stronger biological response to abnormal blood flow. The findings may help researchers develop new ways to identify patients at higher risk of future heart problems and support the development of more personalized approaches to prevention and treatment of coronary artery disease.
Read the detailed description
Coronary artery disease (CAD) is caused by the build-up of atherosclerotic plaques within the coronary arteries. While some plaques remain stable, others continue to grow and may develop features associated with an increased risk of rupture, potentially leading to acute coronary events. Identifying plaques that are likely to progress remains a major challenge in cardiovascular medicine and could enable more personalized prevention and treatment strategies.
Wall shear stress (WSS), the frictional force generated by flowing blood on the vessel wall, plays an important role in vascular biology and atherosclerosis. Previous imaging studies using computational fluid dynamics (CFD) have demonstrated that regions exposed to low WSS are more likely to undergo plaque progression and adverse vascular remodelling. However, low WSS alone has limited predictive accuracy because many plaques exposed to low WSS do not progress over time. This suggests that additional biological factors influence how individual patients respond to adverse flow conditions.
Experimental studies have demonstrated substantial variation between individuals in endothelial cell responses to WSS. Endothelial cells line the inner surface of blood vessels and are key regulators of vascular health. These findings support the hypothesis that plaque progression is influenced not only by local haemodynamic conditions but also by patient-specific biological sensitivity to WSS. The POSSEM (Plaque Prediction Obtained with Shear Stress Endothelial Metrics) study aims to evaluate whether combining local WSS measurements with patient-specific endothelial responses improves prediction of plaque progression compared with assessment of WSS alone.
POSSEM is a prospective, longitudinal interventional study enrolling patients with established CAD who are undergoing coronary revascularisation. Baseline photon-counting computed tomography coronary angiography (PCCTA), performed as part of routine clinical care, will be used to reconstruct patient-specific coronary artery anatomy. Computational fluid dynamics will then be applied to these anatomical models to characterize local haemodynamic parameters, including WSS, within coronary plaques.
A peripheral blood sample will be collected from each participant. Endothelial colony-forming cells will be isolated and cultured to provide a patient-specific assessment of endothelial responsiveness to WSS. In laboratory experiments, these cells will be exposed to flow conditions and analysed for molecular markers associated with endothelial activation, inflammation, and cellular stress responses. These analyses will be used to quantify each participant's biological sensitivity to WSS.
Participants will undergo repeat PCCTA imaging approximately 12 months after the baseline assessment, hence, interventional study. Changes in plaque burden and plaque characteristics between baseline and follow-up scans will be evaluated and related to both local WSS measurements and endothelial responsiveness. The study will investigate whether plaques located in regions of low WSS are more likely to progress in patients demonstrating heightened biological responses to WSS compared with those exhibiting lower responsiveness.
Coronary CT datasets will undergo detailed plaque characterization and three-dimensional vessel reconstruction. CFD modelling will be used to estimate local blood flow patterns and WSS throughout the coronary tree. Plaque morphology and composition will be assessed at baseline and follow-up, enabling assessment of disease progression over time. Endothelial cell studies will be performed using standardized laboratory methods to measure flow-responsive biological pathways.
The study is intended as a proof-of-principle investigation of a combined haemodynamic and biological approach to risk prediction. The use of cultured endothelial cells is a research tool designed to establish whether individual responses to WSS contribute to plaque progression. Although this approach is not expected to be used routinely in clinical practice, the findings may support the future development of simpler blood-based biomarkers capable of identifying patients with heightened sensitivity to adverse flow conditions.
Study participation involves collection of a peripheral blood sample and an additional follow-up PCCTA scan. The repeat PCCTA exposes participants to a small additional dose of ionising radiation and requires administration of iodinated contrast material. Appropriate measures will be taken to minimise these risks, including exclusion of individuals with significant renal impairment or known contrast allergy and the use of standard dose-optimised imaging protocols.
This study seeks to improve understanding of the interaction between coronary blood flow and patient-specific vascular biology in atherosclerosis. By integrating haemodynamic and biological information, the study aims to establish whether a combined WSS-biological signature can improve prediction of coronary plaque progression and inform future strategies for personalized cardiovascular risk assessment.
- Conditions
- Coronary Artery Disease (CAD)
- Being tested
- PCCTA scan, Endothelial cell isolation from peripheral blood sample
- Keywords
- Coronary Artery Disease, Endothelial cell, Wall shear stress, Computational fluid dynamics
- Medical subject headings
- Coronary Artery Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PCCTA scanProcedure or surgery
Also called Naeotom Alpha scanner
During the scans, the patient will be cardiac monitored using ECG synchronisation. PCCTA scan acquisition and parameters will follow Barts Health's standard operating procedures and institutional protocols.
Endothelial cell isolation from peripheral blood sampleOther
A 50mL blood sample will be collected from consenting patients. The blood will be processed to isolate peripheral mononuclear cells. These cells will be cultured to support the growth of endothelial colony forming cells (ECFCs).
| Study group | Role | What they receive |
|---|---|---|
| Single arm | Other | Not described Receives: Procedure: PCCTA scan; Other: Endothelial cell isolation from peripheral blood sample |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage change in plaque burden over 12 months
Percentage change in plaque burden over 12 months, analysed using linear regression with response to WSS as a continuous predictor
Measured: From the first CT scan to the second CT scan- 12 months apart
ECFC isolation from peripheral blood sample
Peripheral blood will be drawn at the point of recruitment. Blood will be processed to culture endothelial colony forming cells (ECFCs).
Measured: The process takes around 4 weeks after blood draw
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Oct 2026
- Study start17 Sep 2026
- Primary completion1 Sep 2031 (estimated)
- Study completion17 Sep 2031 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Coronary Artery Disease (CAD)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- Prospective study
- Masking
- None (open label)
- Enrolment
- 270 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Queen Mary University of London
- Sponsor type
- University, hospital or other
- Collaborators
- Barts & The London NHS Trust
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07864051
- Sponsor's protocol ID
- 367100
- Other IDs
- RG/F/25/110175
- Acronym
- POSSEM
- Status last verified
- Oct 2026
- First submitted
- 22 Sep 2026
- Last updated
- 7 Oct 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 7 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Plaque Prediction Obtained With Shear Stress Endothelial Metrics: A Proof of Principle Study
- ClinicalTrials.gov ID
- NCT07864051
- Acronym / sponsor ID
- POSSEM / 367100
- Conditions
- Coronary Artery Disease (CAD)
- Keywords
- Coronary Artery Disease, Endothelial cell, Wall shear stress, Computational fluid dynamics
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 270 participants (estimated)
- Lead sponsor
- Queen Mary University of LondonUniversity, hospital or other
- Collaborators
- Barts & The London NHS Trust
- Study start
- 17 Sep 2026 (actual)
- Primary completion
- 1 Sep 2031 (estimated)
- Study completion
- 17 Sep 2031 (estimated)
- First posted
- 7 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Coronary artery disease occurs when fatty deposits (plaques) build up inside the arteries that supply blood to the heart. Some plaques remain stable, while others continue to grow or become more likely to rupture, which can lead to a heart attack. Identifying plaques that are at higher risk of progression could help doctors provide earlier and more personalized treatment.
The purpose of this study is to determine whether combining information about blood flow within the coronary arteries with information about a person's biological response to blood flow can improve prediction of plaque growth. Participants undergoing treatment for coronary artery disease will have a specialized heart scan to assess blood flow patterns around plaques in their coronary arteries. Researchers will also collect blood samples to study cells that line blood vessels and investigate how these cells respond to blood flow forces.
The study will follow participants over time to determine whether plaques are more likely to progress in individuals who show a stronger biological response to abnormal blood flow. The findings may help researchers develop new ways to identify patients at higher risk of future heart problems and support the development of more personalized approaches to prevention and treatment of coronary artery disease.
Detailed description
Coronary artery disease (CAD) is caused by the build-up of atherosclerotic plaques within the coronary arteries. While some plaques remain stable, others continue to grow and may develop features associated with an increased risk of rupture, potentially leading to acute coronary events. Identifying plaques that are likely to progress remains a major challenge in cardiovascular medicine and could enable more personalized prevention and treatment strategies.
Wall shear stress (WSS), the frictional force generated by flowing blood on the vessel wall, plays an important role in vascular biology and atherosclerosis. Previous imaging studies using computational fluid dynamics (CFD) have demonstrated that regions exposed to low WSS are more likely to undergo plaque progression and adverse vascular remodelling. However, low WSS alone has limited predictive accuracy because many plaques exposed to low WSS do not progress over time. This suggests that additional biological factors influence how individual patients respond to adverse flow conditions.
Experimental studies have demonstrated substantial variation between individuals in endothelial cell responses to WSS. Endothelial cells line the inner surface of blood vessels and are key regulators of vascular health. These findings support the hypothesis that plaque progression is influenced not only by local haemodynamic conditions but also by patient-specific biological sensitivity to WSS. The POSSEM (Plaque Prediction Obtained with Shear Stress Endothelial Metrics) study aims to evaluate whether combining local WSS measurements with patient-specific endothelial responses improves prediction of plaque progression compared with assessment of WSS alone.
POSSEM is a prospective, longitudinal interventional study enrolling patients with established CAD who are undergoing coronary revascularisation. Baseline photon-counting computed tomography coronary angiography (PCCTA), performed as part of routine clinical care, will be used to reconstruct patient-specific coronary artery anatomy. Computational fluid dynamics will then be applied to these anatomical models to characterize local haemodynamic parameters, including WSS, within coronary plaques.
A peripheral blood sample will be collected from each participant. Endothelial colony-forming cells will be isolated and cultured to provide a patient-specific assessment of endothelial responsiveness to WSS. In laboratory experiments, these cells will be exposed to flow conditions and analysed for molecular markers associated with endothelial activation, inflammation, and cellular stress responses. These analyses will be used to quantify each participant's biological sensitivity to WSS.
Participants will undergo repeat PCCTA imaging approximately 12 months after the baseline assessment, hence, interventional study. Changes in plaque burden and plaque characteristics between baseline and follow-up scans will be evaluated and related to both local WSS measurements and endothelial responsiveness. The study will investigate whether plaques located in regions of low WSS are more likely to progress in patients demonstrating heightened biological responses to WSS compared with those exhibiting lower responsiveness.
Coronary CT datasets will undergo detailed plaque characterization and three-dimensional vessel reconstruction. CFD modelling will be used to estimate local blood flow patterns and WSS throughout the coronary tree. Plaque morphology and composition will be assessed at baseline and follow-up, enabling assessment of disease progression over time. Endothelial cell studies will be performed using standardized laboratory methods to measure flow-responsive biological pathways.
The study is intended as a proof-of-principle investigation of a combined haemodynamic and biological approach to risk prediction. The use of cultured endothelial cells is a research tool designed to establish whether individual responses to WSS contribute to plaque progression. Although this approach is not expected to be used routinely in clinical practice, the findings may support the future development of simpler blood-based biomarkers capable of identifying patients with heightened sensitivity to adverse flow conditions.
Study participation involves collection of a peripheral blood sample and an additional follow-up PCCTA scan. The repeat PCCTA exposes participants to a small additional dose of ionising radiation and requires administration of iodinated contrast material. Appropriate measures will be taken to minimise these risks, including exclusion of individuals with significant renal impairment or known contrast allergy and the use of standard dose-optimised imaging protocols.
This study seeks to improve understanding of the interaction between coronary blood flow and patient-specific vascular biology in atherosclerosis. By integrating haemodynamic and biological information, the study aims to establish whether a combined WSS-biological signature can improve prediction of coronary plaque progression and inform future strategies for personalized cardiovascular risk assessment.
Study design
- Primary purpose
- Basic science
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- Prospective study
| Arm | Type | Receives |
|---|---|---|
| Single arm | Other | Procedure: PCCTA scan, Other: Endothelial cell isolation from peripheral blood sample |
Who may qualify
- Ages
- 40 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Age ≥40
- Stable angina, defined as typical symptoms with evidence of reversible ischemia in non-invasive test and/or documented obstructive coronary artery disease on coronary angiography (>70% stenosis of at least one major epicardial coronary artery or positive fractional flow reserve study)
- Patient that is willing and can provide written informed consent.
Key exclusion criteria (11 listed)
- Acute coronary syndrome within <3 months
- Estimated glomerular filtration rate (eGFR) <60ml/min/1.73m²
- Previous coronary artery bypass surgery
- Decompensated heart failure, or left ventricular ejection fraction ≤30%
- Patient allergic to contrast or cannot receive treatment with aspirin, heparin, or thienopyridines
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| PCCTA scanAlso: Naeotom Alpha scannerDuring the scans, the patient will be cardiac monitored using ECG synchronisation. PCCTA scan acquisition and parameters will follow Barts Health's standard operating procedures and institutional protocols. | Procedure or surgery | Single arm |
| Endothelial cell isolation from peripheral blood sampleA 50mL blood sample will be collected from consenting patients. The blood will be processed to isolate peripheral mononuclear cells. These cells will be cultured to support the growth of endothelial colony forming cells (ECFCs). | Other | Single arm |
Primary outcome
Percentage change in plaque burden over 12 months
Time frame: From the first CT scan to the second CT scan- 12 months apart
Percentage change in plaque burden over 12 months, analysed using linear regression with response to WSS as a continuous predictor
ECFC isolation from peripheral blood sample
Time frame: The process takes around 4 weeks after blood draw
Peripheral blood will be drawn at the point of recruitment. Blood will be processed to culture endothelial colony forming cells (ECFCs).
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Oct 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Coronary Artery Disease (CAD)
Not yet recruitingPhase 1/2
EDIT-401 in Adults Who Require Additional Lowering of Low-Density Lipoprotein Cholesterol (LDL-C)
Heterozygous Familial Hypercholesterolemia (HeFH)
Active, not recruitingPhase 3
Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events
Coronary Artery Disease
Active, not recruiting
Troponin in Acute Chest Pain to Risk Stratify and Guide EffecTive Use of Computed Tomography Coronary Angiography
Coronary Artery Disease
Recruiting
A Prospective, Multicenter, Randomized Controlled Trial to Investigate the Value of Coronary CT Angiography in the Understanding and Management of Coronary Calcium (The Optimal Trial)
Cardiovascular Diseases, Myocardial Ischemia
Active, not recruitingPhase 4
Comparison of Moderate-Intensity Statin Plus Ezetimibe vs. High-Intensity Statin for Coronary Plaque Stabilization
Coronary Artery Disease, Atherosclerosis of Coronary Artery
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing PCCTA scan and Endothelial cell isolation from peripheral blood sample in people with Coronary Artery Disease (CAD), run by Queen Mary University of London at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 7 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Paul C Evans (+447825611695, paul.evans@qmul.ac.uk), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percentage change in plaque burden over 12 months (time frame: From the first CT scan to the second CT scan- 12 months apart). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Oct 2026.